Evidence map›Paper›PMID 28821264›Full record

Trial reportTrials2017

Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: study protocol for a stepped-wedge randomized trial.

Fiona J Walsh, Till Bärnighausen, Wim Delva, Yvette Fleming, Gavin Khumalo, Charlotte L Lejeune, Sikhathele Mazibuko, Charmaine Khudzie Mlambo, Ria Reis, Donna Spiegelman and 2 more

Registry-linked trialOpen access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02909218 (MaxART), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02909218 nacompletednot on this map

MaxART: Early Access to ART for All in Swaziland

TypeinterventionalSponsorClinton Health Access Initiative Inc.Ran2014 to 2017Enrolled3,485ConditionsHIV/AIDSArmsEarly Access to ART for All
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.Journal of acquired immune deficiency syndromes (1999) · 2019
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 7 countries.

Fiona J WalshClinton Health Access Initiative, Boston, MA, USA. fwalsh@clintonhealthaccess.org.
Till BärnighausenHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Wim DelvaThe South African Department of Science and Technology - National Research Foundation (DST-NRF) Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.
Yvette Flemingaidsfonds, Amsterdam, The Netherlands.
Gavin KhumaloSwaziland National Network of People Living with HIV/AIDS (SWANNEPHA), Mbabane, Swaziland.
Charlotte L LejeuneClinton Health Access Initiative, Mbabane, Swaziland.
Sikhathele MazibukoMinistry of Health, Mbabane, Swaziland.
Charmaine Khudzie MlamboClinton Health Access Initiative, Mbabane, Swaziland.
Ria ReisUniversity of Amsterdam, Amsterdam, The Netherlands.
Donna SpiegelmanHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Mandisa ZwaneSAfAIDS, Harare, Zimbabwe.
Velephi OkelloMinistry of Health, Mbabane, Swaziland.
Clinton Health Access Initiative · USMinistry of Health · SZAidsfonds · NLHarvard University · USHeidelberg University · DERega Institute for Medical Research · BESwaziland National Trust Commission · SZUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is robust clinical evidence to support offering early access to antiretroviral treatment (ART) to all HIV-positive individuals, irrespective of disease stage, to both improve patient health outcomes and reduce HIV incidence. However, as the global treatment guidelines shift to meet this evidence, it is still largely unknown if early access to ART for all (also referred to as "treatment as prevention" or "universal test and treat") is a feasible intervention in the resource-limited countries where this approach could have the biggest impact on the course of the HIV epidemics. The MaxART Early Access to ART for All (EAAA) implementation study was designed to determine the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's public sector health system.

methodsThis is a three-year stepped-wedge randomized design with open enrollment for all adults aged 18 years and older across 14 government-managed health facilities in Swaziland's Hhohho Region. Primary endpoints are retention and viral suppression. Secondary endpoints include ART initiation, adherence, drug resistance, tuberculosis, HIV disease progression, patient satisfaction, and cost per patient per year. Sites are grouped to transition two at a time from the control (standard of care) to intervention (EAAA) stage at each four-month step. This design will result in approximately one half of the total observation time to accrue in the intervention arm and the other half in the control arm. Our estimated enrolment number, which is supported by conservative power calculations, is 4501 patients over the course of the 36-month study period. A multidisciplinary, mixed-methods approach will be adopted to supplement the randomized controlled trial and meet the study aims. Additional study components include implementation science, social science, economic evaluation, and predictive HIV incidence modeling. DISCUSSION: A stepped-wedge randomized design is a causally strong and robust approach to determine if providing antiretroviral treatment for all HIV-positive individuals is a feasible intervention in a resource-limited, public sector health system. We expect our study results to contribute to health policy decisions related to the HIV response in Swaziland and other countries in sub-Saharan Africa.

trial registrationClinicalTrials.gov, NCT02909218 . Registered on 10 July 2016.

Indexed as

Early Medical InterventionPublic SectorAnti-Retroviral AgentsClinical ProtocolsCost-Benefit AnalysisDrug Administration ScheduleDrug Resistance, ViralEswatiniFeasibility StudiesHealth Care CostsHIV InfectionsHumansMedication AdherenceOpportunistic InfectionsPatient SatisfactionResearch DesignAnti-Retroviral AgentsAntiretroviral treatmentHIV/AIDSPreventionSwaziland

Identifiers

PMID28821264
PMCPMC5563033
OpenAlexW2748437144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.